Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors CancerOral Drug AdministrationAdvanced Urothelial CarcinomaOpen Label
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Flare Therapeutics Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05929235
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
News
No news found